Oct. 25, 2002 — HIV-positive patients with persistently low CD4 counts despite highly active antiretroviral therapy (HAART) may benefit from interleukin-2, according to results of a multicenter ...
Purpose: Previous preclinical and clinical studies have demonstrated that autologous tumor vaccines can induce relatively specific tumor-reactive T cells in draining lymph nodes. The adoptive transfer ...
BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, ...
Mural Oncology, Alkermes’ cancer spinoff, has officially landed with $275 million in funding and a mission to develop an interleukin-2 (IL-2) candidate for solid tumors. Alkermes announced the plan to ...
This investigator-initiated, double-blind, placebo-controlled study (funded by the Gates Foundation and Alzheimer’s Association) evaluates the safety and tolerability, biological activity, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback